Transcode Therapeutics, Inc.
RNAZNasdaq
$8.43
↑ +1.9%Jul 17 close · end-of-day
Price
1Y↓ -10.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$7.7M
Enterprise Value
-$5.1M
P/E
—
P/S
—
P/B
6.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$40.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-3225.2%
ROIC
—
Debt / Equity
—
Net Cash
$12.8M
Return 1Y
-16.1%
Company profile
TransCode Therapeutics, Inc. engages in the development and commercialization of drugs and diagnostics. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company was incorporated in 2016 and is based in Boston, Massachusetts.
- CEO
- Robert M. Dudley
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 9
- Headquarters
- Massachusetts
- Website
- transcodetherapeutics.com
Earnings
RNAZ Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$21.28↓ -69.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$726,604.00 | -$6.2M | -$18.6M | -$19.4M | -$15.7M | -$28.0M |
| Net income | -$2.3M | -$6.8M | -$17.6M | -$18.5M | -$16.8M | -$34.7M |
| Diluted EPS | -$0.51 | -$0.81 | -$1,082.79 | -$3,419.01 | -$1,336.63 | -$52.59 |
| Operating cash flow | -$492,971.00 | -$5.3M | -$15.8M | -$18.1M | -$13.3M | -$19.5M |
| Free cash flow | — | -$5.5M | -$15.9M | -$18.1M | -$13.4M | -$19.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.1M | -$2.2M | -$5.1M | -$3.2M | -$4.2M | -$4.6M | -$16.0M | -$17.8M |
| Net income | -$5.2M | -$2.3M | -$5.9M | -$12.1M | -$4.3M | -$4.9M | -$13.4M | -$17.8M |
| Diluted EPS | -$680.23 | -$146.06 | -$488.99 | -$70.16 | -$5.13 | -$5.82 | $28.52 | -$21.28 |
| Operating cash flow | -$2.3M | -$3.9M | -$3.1M | -$3.1M | -$4.2M | -$4.1M | -$8.1M | -$5.0M |
| Free cash flow | -$2.3M | -$3.9M | -$3.1M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 8, 2026
Jun 3, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.